TYME-88 Seen to Stop Progression of Recurrent, Non-Metastatic Prostate Cancer in Early Trial Data

TYME-88 Seen to Stop Progression of Recurrent, Non-Metastatic Prostate Cancer in Early Trial Data
Preliminary results from a Phase 1b/2 clinical trial evaluating the safety, pharmacokinetics, and efficacy of  TYME-88 (SM-88) to treat recurrent, non-metastatic prostate cancer found that all eight enrolled patients, who did not yet have lesions detectable on X-rays, did not go on to develop any. The presentations, “SM88 in non-metastatic rising PSA-recurrent prostate cancer,” and “SM88/SMK non-hormonal therapy

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *